| 56S1 Stock | | | EUR 184.25 0.95 0.52% |
Director
Mr. Henri Riey has served as NonExecutive Independent Director of Sartorius Stedim Biotech SA as of June 29, 2007. He is also Member of the Remuneration and Nominating Committee and since December 5, 2007 he has served as Chairman of Company Audit Committee since 2007.
| Age | 57 |
| Tenure | 17 years |
| Phone | 33 4 42 84 56 00 |
| Web | https://www.sartorius.com |
Riey holds a degree from Institut Superieur de Gestion and began his career as Fund Manager at BNP Paribas in 1985. In 1988, he joined Barclays in France as Fund Manager and Head of the European Securities Management team. He was subsequently appointed Director of Research of Barclays Asset Management Europe in 1996 and then Vice President of Barclays Asset Management in charge of all fund management activities in 1999. From 2004 to 2013, Mr. Riey was Director of Finance at Hendyplan S.A. He currently serves as President of Aidea, President of Group HR SAS as well as Traesurer and Secretary General of The Princess Grace Foundation in Monaco.
Sartorius Stedim Management Efficiency
The company has return on total asset
(ROA) of
0.1548 % which means that it generated a profit of $0.1548 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.4143 %, meaning that it generated $0.4143 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.
Sartorius Stedim Biotech has accumulated 1.02
B in total debt with debt to equity ratio
(D/E) of 0.39, which is about average as compared to similar companies. Sartorius Stedim Biotech has a current ratio of 1.47, which is within standard range for the sector. Debt can assist Sartorius Stedim until it has trouble settling it off, either with new capital or with free cash flow. So, Sartorius Stedim's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sartorius Stedim Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sartorius to invest in growth at high rates of return. When we think about Sartorius Stedim's use of debt, we should always consider it together with cash and equity.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTOR STED operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8200 people. Sartorius Stedim Biotech (56S1) is traded on Frankfurt Exchange in Germany and employs 11,934 people.
Management Performance
Sartorius Stedim Biotech Leadership Team
Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Faber, Non-Executive Director | |
| AnneMarie Graffin, Non-Executive Independent Director | |
| Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations | |
| Henri Riey, Non-Executive Independent Director | |
| Pascale Boissel, Non-Executive Independent Director | |
| Olivier Guitard, Head BPS | |
| Joachim Kreuzburg, Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee | |
| Susan Dexter, Non-Executive Independent Director | |
| Heiko Imhl, VP Relations | |
| Amelie Buton, Non-Executive Director, Employee Representative | |
| Lothar Kappich, Non-Executive Director | |
| Benedikt Orzelek, Investor Relations Contact | |
| John Mackay, Sales Marketing | |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Stock
Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.